8F4B
Bovine multidrug resistance protein 1 (MRP1) bound to cyclic peptide inhibitor 1 (CPI1)
8F4B の概要
| エントリーDOI | 10.2210/pdb8f4b/pdb |
| EMDBエントリー | 28854 |
| 関連するBIRD辞書のPRD_ID | PRD_002516 |
| 分子名称 | Multidrug resistance-associated protein 1, Cyclic peptide inhibitor 1 (CPI1) (2 entities in total) |
| 機能のキーワード | transport protein |
| 由来する生物種 | Bos taurus (cattle) 詳細 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 150332.32 |
| 構造登録者 | |
| 主引用文献 | Pietz, H.L.,Abbas, A.,Johnson, Z.L.,Oldham, M.L.,Suga, H.,Chen, J. A macrocyclic peptide inhibitor traps MRP1 in a catalytically incompetent conformation. Proc.Natl.Acad.Sci.USA, 120:e2220012120-e2220012120, 2023 Cited by PubMed Abstract: Adenosine triphosphate-binding cassette (ABC) transporters, such as multidrug resistance protein 1 (MRP1), protect against cellular toxicity by exporting xenobiotic compounds across the plasma membrane. However, constitutive MRP1 function hinders drug delivery across the blood-brain barrier, and MRP1 overexpression in certain cancers leads to acquired multidrug resistance and chemotherapy failure. Small-molecule inhibitors have the potential to block substrate transport, but few show specificity for MRP1. Here we identify a macrocyclic peptide, named CPI1, which inhibits MRP1 with nanomolar potency but shows minimal inhibition of a related multidrug transporter P-glycoprotein. A cryoelectron microscopy (cryo-EM) structure at 3.27 Å resolution shows that CPI1 binds MRP1 at the same location as the physiological substrate leukotriene C4 (LTC). Residues that interact with both ligands contain large, flexible sidechains that can form a variety of interactions, revealing how MRP1 recognizes multiple structurally unrelated molecules. CPI1 binding prevents the conformational changes necessary for adenosine triphosphate (ATP) hydrolysis and substrate transport, suggesting it may have potential as a therapeutic candidate. PubMed: 36893260DOI: 10.1073/pnas.2220012120 主引用文献が同じPDBエントリー |
| 実験手法 | ELECTRON MICROSCOPY (3.27 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






